CARs and other T cell therapies for MM: The clinical experience

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Chimeric antigen receptor (CAR)-T cell therapy has shown success in hematologic malignancies.
• Multiple myeloma (MM) treatment is exploring novel immunotherapeutic approaches.
• Identifying effective non-CD19 targets is crucial for CAR-T cell therapy in MM.

Purpose of the Study:

• To review the current status of adoptive T-cell transfer for multiple myeloma.
• To highlight the challenges and promising targets in CAR-T cell therapy for MM.
• To discuss the potential of T-cell-based therapies in transforming MM treatment.

Main Methods:

• Review of preclinical investigations and early clinical trials.
• Focus on chimeric antigen receptor (CAR)-T cells targeting B-cell maturation antigen (BCMA).
• Exploration of alternative T-cell therapies like T-cell receptor (TCR)-modified cells and TILs.

Main Results:

• Early clinical evaluations of CAR-T cells in multiple myeloma are underway.
• Targeting BCMA shows promising initial results in MM patients.
• Ongoing trials are investigating various CAR constructs, patient selection, and dosing strategies.

Conclusions:

• Adoptive T-cell transfer for multiple myeloma is an emerging field.
• BCMA-targeted CAR-T cell therapy demonstrates potential for MM treatment.
• Durable response rates will determine if this becomes a paradigm-changing therapy for MM.